Earnings

Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival

Oct 26, 2026 · 08:11 AM ET· updated 1h ago

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

Why It Matters

Corcept's cancer medicine showed good results in early testing. Watch to see if the full study confirms these numbers hold up.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CORT89.75

+3.89 (+4.53%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.